Stoke Therapeutics, Inc. Debt Securities, Available-for-sale, Amortized Cost
Stoke Therapeutics, Inc. (STOK) had Debt Securities, Available-for-sale, Amortized Cost of $256.79 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Notes › Credit Losses
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-03
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $256.79M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $255.48M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $306.17M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $244.78M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $256.79M 10-Q · filed 2026-08-03 |
| 2026-03-31 | $255.48M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $306.17M 10-Q · filed 2026-08-03 |
| 2025-09-30 | $244.78M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $253.40M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $105.60M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $118.89M 10-K · filed 2026-03-16 |
| 2024-09-30 | $118.97M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $88.52M 10-Q · filed 2024-08-07 |
| 2023-12-31 | $9.98M 10-K · filed 2025-03-18 |
| 2023-09-30 | $24.89M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $39.77M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $63.93M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $117.21M 10-K · filed 2024-03-25 |
| 2022-09-30 | $139.96M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $209.15M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $209.79M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $75.08M 10-K · filed 2023-03-06 |
| 2021-09-30 | $87.14M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $82.20M 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |